Hypoglycemia and CKD in Type 2 Diabetes
Mr. L is a 62-year-old man with a 12-year history of type 2 diabetes, hypertension, and stage 3b chronic kidney disease. His current medications are metformin 1,000 mg twice daily, gliclazide 80 mg twice daily, ramipril 10 mg daily, and atorvastatin 40 mg daily. Recent labs: HbA1c 8.9%, eGFR 36 mL/min/1.73 m², urine albumin-to-creatinine ratio 350 mg/g, potassium 4.9 mmol/L. BMI is 31 kg/m². In the past month he has had two symptomatic hypoglycemic episodes with capillary glucose 3.1 mmol/L, one while driving to work. He reports no chest pain, no foot ulcers, and no visual symptoms. He asks whether he can “just cut back the metformin” and continue his current regimen. He lives alone, drives daily, and has a home glucose meter but no ketone strips. He has missed two scheduled diabetes visits.
1. Which medication changes would you make now, and what is the reasoning for each? Include doses and monitoring.
Read the worked answer
The priority is to eliminate the agent most likely causing severe hypoglycemia. Stop gliclazide: sulfonylureas cause hypoglycemia, and accumulation is more likely with eGFR 36 mL/min/1.73 m². Reduce metformin to 500 mg twice daily (maximum 1,000 mg/day at eGFR 30–44) rather than stopping it, because it remains useful if renal function is stable. Do not simply continue the current regimen; the driving episode makes recurrence dangerous.
For kidney and cardiovascular protection, consider adding an SGLT2 inhibitor such as dapagliflozin 10 mg daily or empagliflozin 10 mg daily. These can be used at this eGFR and reduce CKD progression and heart failure risk, but they do not cause hypoglycemia when used alone. Counsel about genital mycotic infections, volume depletion, and euglycemic ketoacidosis; provide sick-day rules and consider ketone strips. Continue ramipril and atorvastatin. Recheck electrolytes and creatinine in 1–2 weeks after changes. An individualized HbA1c target of approximately 7.5–8.0% is reasonable given hypoglycemia and CKD. If glucose remains above target, a GLP-1 receptor agonist may be preferable to insulin because of lower hypoglycemia risk, but cost and tolerability matter.
2. How would you counsel him about driving and hypoglycemia?
Read the worked answer
He needs a concrete safety plan, not general advice. Explain that hypoglycemia can impair judgment before symptoms are obvious. He should check capillary glucose before driving and at regular intervals on long trips; if glucose is below 5.0 mmol/L, he should treat with 15 g fast-acting carbohydrate, wait 15 minutes, recheck, and not drive until glucose is above 5.0 mmol/L and stable. He should keep fast sugar in the car and not delay treatment.
If he develops symptoms while driving, he should pull over safely, stop the engine, treat, and wait until fully recovered before resuming. He should not drive if he has had severe hypoglycemia until his regimen has been reviewed and he has been hypoglycemia-free for an appropriate period. Ask about provincial medical fitness reporting requirements; a severe hypoglycemic episode while driving may require reporting. Discuss a glucagon kit and educate a close contact. Review his glucose meter technique and consider continuous glucose monitoring if available. Document the counselling and ensure follow-up within weeks, because his living alone increases the consequences of a recurrent episode.
3. What follow-up and referrals are indicated?
Read the worked answer
Arrange follow-up in 2–4 weeks to review glucose readings, hypoglycemia, blood pressure, and tolerance of the new regimen. Repeat HbA1c in 3 months, and check electrolytes, creatinine, and urine albumin-to-creatinine ratio after medication changes. Reinforce sick-day rules: hold metformin and the SGLT2 inhibitor during vomiting, diarrhea, poor oral intake, or acute illness; seek advice if unable to keep fluids down. Provide ketone strips and explain euglycemic ketoacidosis symptoms.
Refer to a diabetes educator and dietitian for carbohydrate consistency, weight management, and driving safety. Arrange a dilated eye exam and a comprehensive foot exam. Nephrology referral is reasonable because eGFR is below 45 with significant albuminuria, especially if there is rapid decline or difficulty managing medications. Address missed visits by asking about barriers and offering virtual or nurse-led follow-up. Confirm vaccination status. The overall plan should reduce hypoglycemia risk while preserving kidney and cardiovascular protection, rather than intensifying glucose control at the expense of safety.